Recurrent infection and deterioration of lung function are the major causes of morbidity and mortality in cystic fibrosis (CF). Although the genetic defect in CF was discovered in 1989, the mechanisms by which CFTR mutations cause lung disease in CF remain uncertain. This proposal focuses on the role of the airway surface liquid (ASL) and airway submucosal glands in CF lung disease. Our laboratory recently developed a series of novel fluorescent indicators and microscopy methods to measure ASL depth and composition, and submucosal gland secretion rate, fluid composition and viscosity.
Aim 1 will determine whether ASL composition is abnormal in CF, focusing on lower airway function, clinically relevant stresses, and utilizing human tissues.
Aim 2 will determine whether submucosal gland function is defective in CF, focusing on tissues that have not been subject to chronic infection and inflammation.
Aim 3 will examine the hyper-absorption hypothesis (thinned, hyperviscous ASL in CF) and the defective oxygenation hypothesis (hypoxic ASL in CF). Some of the measurements will be done using intact human airways (normal vs. CF), including bronchoscopic biopsies obtained from pediatric CF patients before significant airway disease has developed. Some experiments will utilize potent small-molecule CFFR inhibitors and activators recently developed by our lab. The novel approaches and model systems should provide definitive data on putative abnormalities in ASL composition and submucosal gland function in CF. Understanding of lung disease mechanisms is of central importance in CF research, having direct implications for development of evaluation of new therapies. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL073856-02
Application #
6795096
Study Section
Lung Biology and Pathology Study Section (LBPA)
Program Officer
Banks-Schlegel, Susan P
Project Start
2003-09-01
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$378,750
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Owens, Gregory P; Ritchie, Alanna; Rossi, Andrea et al. (2015) Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG. J Biol Chem 290:12123-34
Asavapanumas, Nithi; Ratelade, Julien; Verkman, A S (2014) Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol 127:539-51
Ye, Long; Hu, Bao; El-Badri, Faris et al. (2014) ?F508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles. Bioorg Med Chem Lett 24:5840-5844
Asavapanumas, Nithi; Ratelade, Julien; Papadopoulos, Marios C et al. (2014) Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation 11:16
Snyder, David S; Tradtrantip, Lukmanee; Battula, Sailaja et al. (2013) ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27. ACS Med Chem Lett 4:456-459
Jin, Byung-Ju; Zhang, Hua; Binder, Devin K et al. (2013) Aquaporin-4-dependent K(+) and water transport modeled in brain extracellular space following neuroexcitation. J Gen Physiol 141:119-32
Verkman, A S (2013) Aquaporins. Curr Biol 23:R52-5
Jin, Byung-Ju; Thiagarajah, Jay R; Verkman, A S (2013) Convective washout reduces the antidiarrheal efficacy of enterocyte surface-targeted antisecretory drugs. J Gen Physiol 141:261-72
Tradtrantip, Lukmanee; Ratelade, Julien; Zhang, Hua et al. (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73:77-85
Verkman, A S; Phuan, Puay-Wah; Asavapanumas, Nithi et al. (2013) Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol 23:684-95

Showing the most recent 10 out of 160 publications